In vitro activity of amphotericin B cochleates against Leishmania chagasi

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 2, 2011, Pages 251-253

  Sesana, Aretha Molina ^a   Monti Rocha, Renata ^a   Vinhas, Solange Alves ^a   Morais, Carlos Gustavo ^a   Dietze, Reynaldo ^a   Lemos, Elenice Moreira ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Amphotericin B cochleates; In vitro activity; Leishmania chagasi

Indexed keywords

AMPHOTERICIN B; ANTIPROTOZOAL AGENT; DRUG CARRIER;

ANIMAL; ARTICLE; DRUG EFFECT; LEISHMANIA INFANTUM; MOUSE; PARASITOLOGY; PERITONEUM MACROPHAGE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG CARRIERS; LEISHMANIA INFANTUM; MACROPHAGES, PERITONEAL; MICE;

LEISHMANIA DONOVANI CHAGASI;

EID: 79955402141     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000200022     Document Type: Article

References (14)

1. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pem-pinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 22: 938-943.
2. Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Per-lin DS 2002. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46: 2704-2707.
3. Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, Luz KG, Suassuna FA, Marinho LA, Ksionski G 1993. Treatment of Brazilian kala-azar with a short course of amphocil (amphoter-icin B cholesterol dispersion). Clin Infect Dis 17: 981-986.
4. Hiemenz JW, Walsh TJ 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22 (Suppl. 2): S133-S144.
5. Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM, Mor A 2010. OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria. FASEB J 24: 5092-5101.
6. Mannino RJ 2010. Cochleate compositions and methods of use. Avaiill-able from: www.wipo.int/pctdb/en/wo.jsp?WO=2010091090.
7. Mannino RJ, Gould-Fogerite S 1997. Antigen cochleate formulations for oral and systemic vaccination. In MM Levine (ed.), New generation vaccines, Marcel Dekker, New York, p. 1-9.
8. Robinson RF, Nahata MC 1999. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther 24: 249-257.
9. Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, Perlin DS 2000. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Che-mother 44: 2356-2360.
10. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW 1997. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 127: 133-137.
11. Syed UM, Woo AF, Plakogiannis F, Jin T, Zhu H 2008. Cochleates bridged by drug molecules. Int J Pharm 363: 118-125.
12. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26: 1383-1396.
13. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ 2000. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 44: 1463-1469.
14. Zarif L, Mannino RJ 2000. Cochleates: lipid-based vehicles for gene delivery concept, achievements and future development, In N Habib (ed.), Cancer gene therapy: past achievements and future challenges, Plenum Publishing Co, London, p. 83-94.